| Novartis eye drug works with fewer injections than rival | | | ZURICH (Reuters) - A Novartis drug to treat a leading cause of vision loss in people over 65 does not need to be injected as frequently as a rival medicine from Regeneron Pharmaceuticals to be effective, clinical trials showed on Tuesday. |
| |
| Shire wins U.S. approval for long-acting ADHD drug | | | (Reuters) - Shire has won U.S. approval for a long-acting attention deficit drug aimed at adolescents and adults, boosting its stock of medicines for the cognitive condition that affects millions of children and is being diagnosed more in older people. |
| |
| Worldwide drug sale forecasts fall as pricing pressures mount | | | LONDON (Reuters) - Forecasts for global sales of pharmaceuticals have declined for the first time in a decade as continuing pressure on prices in the key U.S. market has caused analysts to moderate revenue expectations, according to a report on Tuesday. |
| |
| Screen kids and teens for obesity, U.S. experts say | | | (Reuters Health) - Children and teens should be screened for obesity at doctors' offices starting at age 6 and advised to attend intensive weight management programs if needed, according to a U.S.-government backed panel. |
| |
| Many Americans taking too much vitamin D | | | (Reuters Health) - Nearly one in five U.S. adults are taking supplemental vitamin D, and a growing number are taking excessively high doses linked to an increased risk of fractures, falls, kidney stones and certain cancers, a new study suggests. |
| |
| | |
